Clinical Trials
11 trialsNCT03237377 2026-05-27
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03875235 2026-05-26
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
NCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT04163432 2026-05-19
STAGGER
University of Utah
Phase 2 Active not recruiting
NCT04068610 2026-05-15
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
NCT03706690 2026-05-13
PACIFIC-5
AstraZeneca
Phase 3 Active not recruiting
NCT02453282 2026-05-12
MYSTIC
AstraZeneca
Phase 3 Active not recruiting
NCT03459846 2026-05-11
BAYOU
AstraZeneca
Phase 2 Active not recruiting
NCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT04786093 2026-05-05
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT03660826 2026-05-04
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting